Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774139 | 0.78 | ALDH1A1 (0.45) | — | |
| SCHEMBL25778915 | 0.76 | SLC22A12 (0.43) | DHODHCYP11B2NOTUMCYP11B1MMP3 | |
| SCHEMBL9114552 | 0.71 | DHODH (0.43) | DHODHCYP11B2CYP11B1 | |
| SCHEMBL21172100 | 0.69 | CYP11B1 (0.44) | DHODHCYP11B2CYP11B1CYP19A1 | |
| SCHEMBL16094180 | 0.68 | GSK3B (0.44) | CYP11B2NOTUMCYP11B1MMP3MAOA | |
| SCHEMBL2511386 | 0.68 | SLC22A12 (0.49) | CYP11B2CYP11B1SLC22A12 | |
| SCHEMBL5771770 | 0.67 | CYP11B2 (0.41) | DHODHCYP11B2CYP11B1MMP3SLC22A12 | |
| SCHEMBL2744983 | 0.66 | XDH (0.47) | CYP11B2MMP3MAOAMAOBCA12 | |
| SCHEMBL31626634 | 0.66 | SMN1; SMN2 (0.49) | CYP11B2CYP11B1 | |
| SCHEMBL3189884 | 0.65 | HDAC2 (0.53) | CYP11B2MMP3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | DHODH 226/4885CYP11B2 244/4885NOTUM 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.